In treated MS, early disease activity predicts poor outcome

In treated MS, early disease activity predicts poor outcome
After 15 years of follow-up, patients with relapsing-remitting multiple sclerosis who display disease activity despite treatment with interferon β-1a tend to have unfavorable long-term outcomes, according to research published online Sept. 13 in the Annals of Neurology.

(HealthDay)—After 15 years of follow-up, patients with relapsing-remitting multiple sclerosis (RRMS) who display disease activity despite treatment with interferon (IFN)β-1a tend to have unfavorable long-term outcomes, according to research published online Sept. 13 in the Annals of Neurology.

Robert A. Bermel, M.D., of the Cleveland Clinic, and colleagues conducted a multicenter, observational, 15-year follow-up study involving 136 patients with RRMS, who had initially been treated with either intramuscular (IM) IFNβ-1a or placebo, to identify early predictors of long-term outcomes.

The researchers found that significantly fewer patients treated with IM IFNβ-1a had early disease activity. Of those treated with IFNβ-1a, activity was associated with an 8.96-fold higher risk of gadolinium-enhancing lesions, a 4.44-fold higher risk of relapse, and a 2.90-fold higher risk of new T2 lesions. Conversely, early disease activity in placebo-treated patients was not associated with long-term outcomes.

"Disease activity despite treatment with IFNβ is associated with unfavorable long-term outcomes. Particular attention should be paid to gadolinium-enhancing lesions on IFNβ therapy, as their presence strongly correlates with severe disability 15 years later," the authors write. "The results provide rationale for monitoring IFNβ treated patients with , and for changing therapy in patients with active disease."

This study was supported by Biogen Idec.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Fingolimod: 'Hint' of advantages in a small group of patients

Jul 05, 2012

The immunosuppressive drug fingolimod (trade name: Gilenya) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform ...

Recommended for you

Dallas hospital confirms first Ebola case in US

52 seconds ago

A patient at a Dallas hospital has tested positive for Ebola, the first case of the disease to be diagnosed in the United States, federal health officials announced Tuesday.

First case of Ebola diagnosed in US

1 hour ago

The United States has diagnosed its first case of the deadly Ebola virus in a man who became infected in Liberia and traveled to Texas, US health officials said Tuesday.

Study finds acupuncture does not improve chronic knee pain

2 hours ago

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the ...

Ebola outbreak nears end in Nigeria

2 hours ago

The Ebola outbreak in Nigeria is almost over, US health officials said Tuesday, in a rare sign of authorities turning the tide on the highly contagious disease that has killed more than 3,000 in West Africa.

User comments